Bringing Decades of Experience to Propel Global Growth for Herspiegel
Yardley, PA – September 25, 2024 – Herspiegel, a leading partner in commercialization strategy and implementation services for the pharmaceutical and biotech sectors, proudly announces the appointment of Eric Matckie as Chief Growth Officer. As the company experiences unprecedented growth, Eric’s leadership will be pivotal in expanding its innovative solutions and driving further success.
With over 30 years of experience in the Life Sciences industry, Eric brings a wealth of expertise in go-to-market strategies, market access, commercial analytics, and operational excellence. He has a proven track record of advising global pharmaceutical giants and dynamic biotech startups alike, specializing in pricing, reimbursement, local market analytics, health systems, and pull-through strategies.
"As we expand our global footprint with seven offices across five countries, we're entering an exciting phase of growth. Eric’s appointment as Chief Growth Officer marks a pivotal moment for Herspiegel. We are well-positioned to continue driving innovation for our clients as we scale and deliver best-in-class commercialization services worldwide."
Herspiegel has an established reputation as a partner of choice for start-ups and large pharma launch readiness and aims to maintain this momentum with Eric Matckie as Chief Growth Officer. Leveraging Eric’s expertise, the company will continue to leverage cross-functional commercial expertise and innovation to meet the needs of clients in the dynamic life sciences landscape.
Eric Matckie will assume his role immediately, spearheading initiatives aimed at accelerating growth and innovation at Herspiegel.
ABOUT HERSPIEGEL
Herspiegel provides world-class commercialization services helping biotech start-ups and the world’s largest pharmaceutical companies unlock their commercial potential. We are committed to solving critical issues and complex problems through our expertise and insights from medical, market access, marketing, and commercial.
